Geneva, June 16 -- International Clinical Trials Registry received information related to the study (ISRCTN87163290) titled 'A clinical trial of Baricitinib in Juvenile Dermatomyositis (BAR-JDM): comparing baricitinib and steroids to methotrexate and steroids over 52 weeks' on June 3.
Study Type: Interventional
Study Design:
Interventional open-label randomized parallel-group controlled trial (Safety, Efficacy)
Primary Sponsor: University College London
Condition:
Juvenile dermatomyositis (JDM)
Musculoskeletal Diseases
Intervention:
a. Trial arms:
i. Experimental arm: Baricitinib and glucocorticoids
i. Control arm: Methotrexate and glucocorticoids (standard of care)
b. Baricitinib:
i. Dose range: Minimum 2mg to maximum 10mg....